Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19.
Hocini H, Wiedemann A, Blengio F, Lefebvre C, Cervantes-Gonzalez M, Foucat E, Tisserand P, Surenaud M, Coléon S, Prague M, Guillaumat L, Krief C, Fenwick C, Laouénan C, Bouadma L, Ghosn J, Pantaleo G, Thiébaut R; French COVID cohort study group; Lévy Y. Hocini H, et al. Among authors: guillaumat l. J Clin Immunol. 2023 Jul;43(5):894. doi: 10.1007/s10875-023-01477-9. J Clin Immunol. 2023. PMID: 36991251 Free PMC article. No abstract available.
Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19.
Hocini H, Wiedemann A, Blengio F, Lefebvre C, Cervantes-Gonzalez M, Foucat E, Tisserand P, Surenaud M, Coléon S, Prague M, Guillaumat L, Krief C, Fenwick C, Laouénan C, Bouadma L, Ghosn J, Pantaleo G, Thiébaut R; French COVID cohort study group; Lévy Y. Hocini H, et al. Among authors: guillaumat l. J Clin Immunol. 2023 Jul;43(5):882-893. doi: 10.1007/s10875-023-01459-x. Epub 2023 Mar 21. J Clin Immunol. 2023. PMID: 36943669 Free PMC article.
Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients.
Wiedemann A, Pellaton C, Dekeyser M, Guillaumat L, Déchenaud M, Krief C, Lacabaratz C, Grimbert P, Pantaleo G, Lévy Y, Durrbach A. Wiedemann A, et al. Among authors: guillaumat l. Front Med (Lausanne). 2022 Aug 22;9:978764. doi: 10.3389/fmed.2022.978764. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36072955 Free PMC article.
T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial.
Richert L, Lelièvre JD, Lacabaratz C, Hardel L, Hocini H, Wiedemann A, Lucht F, Poizot-Martin I, Bauduin C, Diallo A, Rieux V, Rouch E, Surenaud M, Lefebvre C, Foucat E, Tisserand P, Guillaumat L, Durand M, Hejblum B, Launay O, Thiébaut R, Lévy Y; ANRS VRI01 Study Group. Richert L, et al. Among authors: guillaumat l. J Immunol. 2022 Jun 15;208(12):2663-2674. doi: 10.4049/jimmunol.2101076. Epub 2022 May 25. J Immunol. 2022. PMID: 35613727 Clinical Trial.
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, Foucat E, Surenaud M, Guillaumat L, Boilet V, Rieux V, Bouchaud O, Girard PM, Molina JM, Morlat P, Hocqueloux L, Richert L, Pantaleo G, Lelièvre JD, Thiébaut R. Lévy Y, et al. Among authors: guillaumat l. J Virol. 2021 Apr 12;95(9):e02165-20. doi: 10.1128/JVI.02165-20. Print 2021 Apr 12. J Virol. 2021. PMID: 33568510 Free PMC article. Clinical Trial.
119 results